We try to begin with the lowest dose and increase to a higher dose when necessary to minimize common side effects
Hyperimmune activation and autoimmunity are considered as potential causative factors in the onset of PASC 225
Explorations in statistics: the analysis of ratios and normalized data
CVOTs on DPP-4i Data from TECOS, EXAMINE, SAVOR-TIMI53, CARMELINA, and CAROLINA showed that DPP-4i are non-inferior to the placebo or glimepiride relative to primary cardiovascular endpoints [17, 48, 49, 57, 58]
The lyophilized powder should be intact and the vial should be sealed
According to NICE guidance, healthcare professionals should provide clear safety-netting advice when prescribing GLP-1 receptor agonists, including information about expected side effects and warning signs requiring medical review